USRM
vs
S&P 500
USRM
S&P 500
Over the past 12 months, USRM has underperformed S&P 500, delivering a return of 0% compared to the S&P 500's +30% growth.
Stocks Performance
USRM vs S&P 500
Performance Gap
USRM vs S&P 500
Performance By Year
USRM vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US Stem Cell Inc
Glance View
U.S.Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company that is focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of disease and injury. Its MyoCell and MyoCell SDF-1 product candidates are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Its Adipocell product is a cell therapy with a range of treatment applications using autologous adipose cells. The firm's business includes the development of cell therapy products, distribution of regenerative medicine products, as well as physician and patient-based regenerative medicine/cell therapy training services. The firm operates through its US Stem Cell Training, Inc. (SCT) and Vet biologics (VBI) divisions.
